Global Short Bowel Syndrome Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The global short bowel syndrome (SBS) market is segmented by drug class into intestinal growth factors, parenteral nutrition (PN), and other supportive therapies. Intestinal growth factors, such as teduglutide, are designed to stimulate the growth of the remaining intestine, improving nutrient absorption and reducing the dependency on parenteral nutrition. Parenteral nutrition is a critical drug class for SBS patients, providing necessary nutrients through intravenous feeding when oral intake or absorption is insufficient. Other supportive therapies include medications to manage symptoms like diarrhea, pain, or infection, as well as drugs to promote gut motility and nutrient absorption. As treatment options advance, biologics and novel therapies are expected to improve patient outcomes and reduce reliance on long-term nutritional support.

The distribution channel segment includes hospitals, specialty clinics, and retail pharmacies. Hospitals are the largest distribution channel for SBS treatments, as patients with severe forms of the condition often require inpatient care, intensive monitoring, and specialized therapies like parenteral nutrition. Specialty clinics, particularly those focused on gastroenterology or nutrition, are key for ongoing management, especially for patients who need regular follow-ups and adjustments to their treatment regimen. Retail pharmacies are also important for dispensing oral medications and providing access to home-based therapies, especially as the management of SBS increasingly shifts to outpatient care with more at-home treatment options. Online pharmacies are emerging as a growing distribution channel, offering convenience for patients to receive medications or nutritional supplies.

Geographically, North America holds the largest market share for SBS treatment, driven by advanced healthcare infrastructure, high awareness of the disease, and widespread access to specialized therapies such as parenteral nutrition and growth factor treatments. Europe also represents a significant portion of the market, with a robust healthcare system and increasing focus on improving quality of life for SBS patients through advanced therapeutic approaches. The Asia-Pacific region is anticipated to experience rapid growth due to rising healthcare expenditure, an increasing prevalence of gastrointestinal diseases, and expanding access to modern therapies. As awareness of SBS improves in developing countries and healthcare systems evolve, the demand for effective treatments and management solutions is expected to rise in this region.

Global Short Bowel Syndrome Segment Analysis

In this report, the Global Short Bowel Syndrome Market has been segmented by Drug Class, Distribution Channel and Geography.

Global Short Bowel Syndrome Market, Segmentation by Drug Class

The Global Short Bowel Syndrome Market has been segmented by Drug Class into Glucagon-like Peptide-2 (GLP-2), Growth Hormone, Glutamine and Others.

The anticipated growth of the global short bowel syndrome market from 2024 to 2030 is driven by a combination of factors, including advancements in therapeutic options and an increasing prevalence of gastrointestinal disorders. These advancements in therapeutic options, segmented by drug class such as glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others, offer diverse mechanisms of action to address the multifaceted nature of short bowel syndrome. By targeting specific aspects of the condition's pathophysiology, such as promoting intestinal adaptation and enhancing nutrient absorption, these drugs aim to alleviate symptoms and improve the quality of life for patients with short bowel syndrome.

Moreover, the growing awareness among healthcare providers and patients about short bowel syndrome is expected to contribute to market growth. With increased recognition of the condition's impact on patients' lives and the availability of innovative treatment options, there is a heightened focus on early diagnosis and comprehensive management strategies. As research and development efforts continue to yield novel therapies and therapeutic approaches, the global short bowel syndrome market is poised to expand, offering new hope and improved outcomes for individuals affected by this challenging gastrointestinal disorder.

Global Short Bowel Syndrome Market, Segmentation by Distribution Channel

The Global Short Bowel Syndrome Market has been segmented by Distribution Channel into Hospital Pharmacies and Online & Retail Pharmacies.

The global short bowel syndrome (SBS) market, segmented by distribution channel, includes hospital pharmacies and online & retail pharmacies. Hospital pharmacies play a pivotal role in providing specialized treatments for SBS patients, particularly for those requiring complex therapies like parenteral nutrition (PN), intravenous medications, and growth factors such as teduglutide. Hospital pharmacies are equipped to handle the unique needs of SBS patients, ensuring that they receive the correct dosage and therapy under medical supervision. These pharmacies also offer personalized care and consultations for patients, providing a higher level of service in a clinical setting.

Online and retail pharmacies have seen an increase in demand for SBS-related treatments due to the growing trend of home-based care. Online pharmacies offer the convenience of ordering medications, nutritional supplies, and accessories necessary for managing SBS from the comfort of home, which is especially important for patients who require long-term management and prefer not to visit hospitals or clinics frequently. Retail pharmacies, on the other hand, are critical in providing easily accessible medications for SBS management, including oral medications to control symptoms like diarrhea or pain. These pharmacies provide quick access to treatments and allow for a wider distribution of SBS-related medications, improving patient convenience and adherence to treatment regimens.

Geographically, hospital pharmacies are more prominent in developed regions such as North America and Europe, where patients often require inpatient care and intensive monitoring, particularly for severe cases of SBS. In contrast, online and retail pharmacies are growing rapidly in regions like Asia-Pacific and Latin America, where patients benefit from the convenience of accessing medications and home-based treatment options. The increasing reliance on online platforms for medical supplies, especially for chronic conditions like SBS, is expected to fuel the demand for these distribution channels in the coming years, making treatment more accessible and affordable for a broader patient base.

Global Short Bowel Syndrome Market, Segmentation by Geography

In this report, the Global Short Bowel Syndrome Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Short Bowel Syndrome Market Share (%), by Geographical Region, 2024

Geographically, the global short bowel syndrome market is divided into key regions, including North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America and Europe are anticipated to dominate the market shares due to their well-established healthcare infrastructures, high prevalence rates of gastrointestinal disorders, and favorable regulatory environments for drug approval. These regions also benefit from substantial investments in research and development activities, fostering innovation in therapeutic options for short bowel syndrome. Additionally, the presence of key market players and advanced healthcare systems further contribute to market growth in North America and Europe.

On the other hand, the Asia Pacific region is poised to witness significant growth during the forecast period, driven by factors such as rising healthcare expenditure, expanding patient populations, and improving access to medical services. As healthcare infrastructure continues to develop and awareness about short bowel syndrome increases among healthcare providers and patients, emerging markets in Latin America and the Middle East and Africa are also expected to contribute to market expansion. Overall, the global short bowel syndrome market is projected to experience substantial growth, propelled by expanding therapeutic options and increasing demand across diverse geographic regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Short Bowel Syndrome Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Advancements in Therapeutic Options

• Increasing Prevalence of Gastrointestinal Disorders:The rising prevalence of gastrointestinal disorders, such as Crohn's disease and intestinal resections, contributes to the growing patient population with short bowel syndrome. As the incidence of these underlying conditions increases globally, so does the demand for effective treatments for short bowel syndrome, driving market growth.
  
  Ongoing research and development efforts have led to advancements in therapeutic options for short bowel syndrome, including novel drugs and treatment approaches. These advancements offer improved efficacy and tolerability, providing patients with more effective management of their condition and better quality of life.

Restraints

• Limited Awareness and Diagnosis:

• High Treatment Costs:The cost of treatment for short bowel syndrome, including medications, nutritional support, and surgical interventions, can be significant. High treatment costs may pose a barrier to access for some patients, particularly in regions with limited healthcare resources or inadequate insurance coverage, restraining market growth.
  
  Short bowel syndrome is a complex and often underdiagnosed condition, leading to limited awareness among healthcare providers and patients. This lack of awareness may result in delays in diagnosis and treatment initiation, hindering market growth and impacting patient outcomes.

Opportunities

• Emerging Markets

• Technological Innovations:Technological advancements in drug delivery systems and medical devices offer opportunities for innovation in short bowel syndrome treatment. Novel delivery methods and devices may improve treatment efficacy, patient adherence, and convenience, enhancing the overall patient experience and driving market growth.
  
  Emerging markets in regions such as Asia Pacific, Latin America, and the Middle East and Africa present significant growth opportunities for the short bowel syndrome market. As healthcare infrastructure improves and awareness about the condition increases in these regions, there is a growing demand for effective treatments, driving market expansion.

Key players in Global Short Bowel Syndrome Market includ:

• Shire plc (Takeda Pharmaceutical Company Limited)
• Zealand Pharma A/S
• Sancilio & Company, Inc.
• OxThera
• Nutrinia Ltd
• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• GLyPharma Therapeutic, Inc. (Pfizer Inc.)
• Merck KGaA
• Naia Pharmaceuticals

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis